Odyssey Therapeutics (NASDAQ:ODTX) Releases Quarterly Earnings Results

Odyssey Therapeutics (NASDAQ:ODTX) posted its quarterly earnings results on Wednesday. The company reported ($1.74) earnings per share for the quarter, FiscalAI reports.

Odyssey Therapeutics Stock Performance

ODTX traded up $0.66 during trading on Thursday, reaching $21.55. 123,152 shares of the stock were exchanged, compared to its average volume of 254,668. The stock’s 50 day moving average price is $17.78. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $22.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Cantor Fitzgerald started coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “overweight” rating for the company. Zacks Research raised shares of Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a report on Thursday, June 18th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Buying and Selling

In other news, Director Shelley Chu purchased 11,111 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the transaction, the director directly owned 11,111 shares in the company, valued at $199,998. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $18.00, for a total transaction of $32,040.00. Following the completion of the sale, the insider owned 440,981 shares in the company, valued at $7,937,658. This represents a 0.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have acquired 4,183,777 shares of company stock valued at $75,319,986 in the last three months.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.